Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NCDx
- Development stage
- Preclinical
- Lead developer
- Flavocure Biotech
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NCDx (NanoCaflanone diagnostic) is a preclinical-stage, noninvasive molecular magnetic resonance imaging (mMRI) probe developed by Flavocure Biotech in partnership with Baylor College of Medicine. Built on the NanoCaflanone™ platform, NCDx consists of PEGylated caflanone (a cannabis-derived flavonoid) conjugated to nanoparticles. It is designed to cross the blood-brain barrier (BBB) and target colony-stimulating factor 1 receptor (CSF1-R), which is highly enriched on activated microglia and tumor-associated microglia/macrophages (TAMMs). By binding to the extracellular Ig-like domain of CSF1-R, NCDx is internalized by these cells, enabling high-resolution MRI imaging of neuroinflammation and tumor microenvironments. It is being developed for the early diagnosis, longitudinal monitoring, and precision targeting of central nervous system (CNS) disorders, such as Parkinson's disease and Alzheimer's disease, as well as oncology indications.
- Other names
- NCDXNanoCaflanone diagnosticNanoCaflanone diagnostic probe
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on NCDx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NCDx.